Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience
Lynette Marie Sholl, Dara L. Aisner, Marileila Varella‐Garcia et al. · Journal of Thoracic Oncology · 2015
Cited by 429 works. doi:10.1097/jto.0000000000000516
Authors
- Lynette Marie Sholl
- Dara L. Aisner
- Marileila Varella‐Garcia
- Lynne D. Berry
- Dora C. Dias-Santagata
- Ignacio Ivan Wistuba
- Heidi Chen
- Junya Fujimoto
- Kelly Kugler
- Wilbur A. Franklin
- Anthony John Iafrate
- Marc Ladanyi
- Mark G. Kris
- Bruce Evan Johnson
- Paul A. Bunn
- John Dorrance Minna
- David J. Kwiatkowski
References
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
- Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs